Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
GL Beretta, G Cassinelli, M Pennati, V Zuco… - European journal of …, 2017 - Elsevier
Resistance to conventional and target specific antitumor drugs still remains one of the major
cause of treatment failure and patience death. This condition often involves ATP-binding …
cause of treatment failure and patience death. This condition often involves ATP-binding …
[HTML][HTML] T790M and acquired resistance of EGFR TKI: a literature review of clinical reports
C Ma, S Wei, Y Song - Journal of thoracic disease, 2011 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects
Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …
[HTML][HTML] Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells
Background The sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine
kinase inhibitors (TKIs) is strongly associated with activating EGFR mutations. Although not …
kinase inhibitors (TKIs) is strongly associated with activating EGFR mutations. Although not …
[HTML][HTML] Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study
Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …
Local therapy for oligoprogressive disease in patients with advanced stage non–small-cell lung cancer harboring epidermal growth factor receptor mutation
B Qiu, Y Liang, QW Li, GH Liu, F Wang, ZL Chen… - Clinical Lung Cancer, 2017 - Elsevier
Introduction The effect of local therapy (LT) for oligoprogressive epidermal growth factor
receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) has not been well …
receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) has not been well …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
[HTML][HTML] Efficacy and safety of gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with first-line gefitinib followed by second-line …
Y Song, YL Wu, LJ Cao, JH Chen, ZY Ma… - American Journal of …, 2019 - journals.lww.com
Objective: There is no standard care for advanced non–small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study …
patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study …
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung
F Conforti, C Catania, F Toffalorio, M Duca, G Spitaleri… - Lung Cancer, 2013 - Elsevier
Introduction Recent data show that EGFR pathway and its inhibition maintain their role after
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …